A new look at the eye: aldosterone and mineralocorticoid receptors as novel targets in retinal vasculopathy.
Touyz
Rhian M
RM
Callera
Glaucia E
GE
D000450:Aldosterone / Q000502:physiology*; D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects / Q000502:physiology; D002417:Cattle; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000503:physiopathology; D016503:Drug Delivery Systems; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D019255:NADPH Oxidases / Q000502:physiology; D009389:Neovascularization, Pathologic / Q000503:physiopathology / Q000517:prevention & control; D018384:Oxidative Stress; D011817:Rabbits; D051381:Rats; D017382:Reactive Oxygen Species / Q000378:metabolism; D018161:Receptors, Mineralocorticoid / Q000502:physiology*; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D031300:Retinal Vasculitis / Q000188:drug therapy* / Q000503:physiopathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000502:physiology
D020533:Angiogenesis Inhibitors; D047228:Angiotensin II Type 1 Receptor Blockers; D000451:Mineralocorticoid Receptor Antagonists; D017382:Reactive Oxygen Species; D018161:Receptors, Mineralocorticoid; D042461:Vascular Endothelial Growth Factor A; D000450:Aldosterone; D019255:NADPH Oxidases